Overexpression of BMI-1 promotes cell growth and resistance to cisplatin treatment in osteosarcoma

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Wu, Zhihong ^a   Min, Li ^a   Chen, Dafu ^b   Hao, Dongsheng ^a   Duan, Yuanhui ^a   Qiu, Guixing ^a   Wang, Yipeng ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b SINOPEC BEIJING RESEARCH INSTITUTE OF CHEMICAL INDUSTRY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; CASPASE 3; CASPASE 9; CISPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; BMI1 PROTEIN, MOUSE; NUCLEAR PROTEIN; ONCOPROTEIN; REPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE SILENCING; GENETIC REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; PHENOTYPE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; TUMOR GROWTH; ANIMAL; BONE TUMOR; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; DRUG EFFECT; DRUG RESISTANCE; EVALUATION; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; UPREGULATION;

LENTIVIRUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; MICE, TRANSGENIC; NUCLEAR PROTEINS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 79551641545     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014648     Document Type: Article

References (25)

1. Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115: 1531-1543.
2. Ferrari S, Briccoli A, Mercuri M, Bertoni F, Picci P, et al. (2003) Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 21: 710-715.
3. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, et al. (2005) Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23: 8845-8852.
4. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, et al. (1991) Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65: 737-752.
5. Raaphorst FM (2003) Self-renewal of hematopoietic and leukemic stem cells: a central role for the Polycomb-group gene BMI-1. Trends Immunol 24: 522-524.
6. Molofsky AV, He S, Bydon M, Morrison SJ, Pardal R (2005) BMI-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Gene Dev 19: 1432-1437.
7. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M (1999) The oncogene and Polycomb-group gene BMI-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397: 164-168.
8. Dukers DF, van Galen JC, Giroth C, Jansen P, Sewalt RG, et al. (2004) Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol 164: 873-881.
9. van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, et al. (2001) Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97: 3896-3901.
10. Bachmann IM, Puntervoll HE, Otte AP, Akslen LA (2008) Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Mod Pathol 21: 583-590.
11. Cui H, Hu B, Li T, Ma J, Alam G, et al. (2007) BMI-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol 170: 1370-1378.
12. Engelsen IB, Mannelqvist M, Stefansson IM, Carter SL, Beroukhim R, et al. (2008) Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. Br J Cancer 98: 1662-1669.
13. Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, et al. (2001) The BMI-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 84: 1372-1376.
14. Datta S, Hoenerhoff MJ, Bommi P, Sainger R, Guo WJ, et al. (2007) BMI-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways. Cancer Res 67: 10286-10295.
15. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, et al. (2006) BMI-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 66: 6225-6232.
16. Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115: 1503-1521.
17. Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, et al. (2002) The BMI-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 62: 4736-4745.
18. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, et al. (2006) Hedgehog signaling and BMI-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66: 6063-6071.
19. Qin L, Zhang X, Zhang L, Feng Y, Weng GX, et al. (2008) Downregulation of BMI-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells. Biochem Biophys Res Commun 371: 531-535.
20. Meltzer PS (2007) Is Ewing's sarcoma a stem cell tumor? Cell Stem Cell 1: 13-15.
21. Hosen N, Yamane T, Muijtjens M, Pham K, Clarke MF, et al. (2007) BMI-1- green fluorescent protein-knock-in mice reveal the dynamic regulation of BMI-1 expression in normal and leukemic hematopoietic cells. Stem Cells 25: 1635-1644.
22. Douglas D, Hsu JH, Hung L, Cooper A, Abdueva D, et al. (2008) BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res 68: 6507-6515.
23. Cohen GM (1997) Caspases: the executioners of apoptosis. Biochem J 326: 1-16.
24. Brognard J, Clark AS, Ni Y (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997.
25. Huang WC, Hung MC (2009) Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 108: 180-194.